The burgeoning landscape of medication for weight management and type 2 diabetes is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant distinctions in their pharmacological profiles

Emerging in the arena of excess body fat management, retatrutide represents a different method. Beyond many current medications, retatrutide functions as a twin agonist, concurrently affecting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. T